Protocol Ledger

NCT03805789 · Phase II/III · TERMINATED

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

Interventional Phase II/III clinical trial protocol NCT03805789 sponsored by CSL Behring in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-27 Enrollment: 222 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03805789
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)222 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03805789
Protocol FieldVerified Registry Value
NCT IdentifierNCT03805789
Consolidated Lead SponsorCSL Behring
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment222 participants (ACTUAL)
Registered Start Date2019-03-27
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI